Adenosinergic approaches to stroke therapeutics.

Area of Science:

• Neuroscience
• Pharmacology
• Neurology

Background:

• Excitatory amino acids (EAAs), like glutamic and aspartic acid, are implicated in neurodegeneration.
• Overactivity of the EAA system, termed delayed excitotoxicity, contributes to neural tissue damage after cerebral ischemia and in other neurodegenerative diseases.

Purpose of the Study:

• To explore the therapeutic potential of adenosinergic approaches for stroke and neurodegenerative diseases.
• To compare the efficacy of adenosine A1 receptor agonists with EAA receptor blockers in mitigating excitotoxicity.

Main Methods:

• Investigated the use of adenosine A1 receptor agonists to inhibit pre-synaptic EAA release.
• Examined the effects of adenosine agonists on granulocyte activation and the no-reflow phenomenon.
• Considered brain-permeable adenosine uptake blockers to increase localized adenosine levels at ischemic foci.

Main Results:

• Adenosine A1 receptor agonists effectively reduce post-stroke neurological damage in animal models.
• Adenosine agonists demonstrate advantages over EAA receptor blockers by also inhibiting granulocyte activation and the no-reflow phenomenon.
• Increased adenosine levels via uptake blockers show potential for inhibiting EAA release.

Conclusions:

• The adenosinergic approach, utilizing A1 receptor agonists or uptake blockers, presents a promising therapeutic strategy for stroke.
• This approach may have broader applications in treating neurodegenerative conditions associated with excitotoxicity.
• Adenosine-based therapies offer a potentially more effective and multifaceted treatment for neurological damage compared to EAA receptor blockers.